Arguably the biggest news of the month from an M&A perspective was the merger of Netherlands-incorporated Mylan (Nasdaq: MYL) and the off-patent business of New York-based pharma giant Pfizer (NYSE: PFE), creating a generics powerhouse.
But it was by no means the only noteworthy activity, with other big names also announcing acquisitions, including Gilead Sciences (Nasdaq: GILD), AbbVie (Nadaq: ABBV), Boehringer Ingelheim and Roche's (ROG: SIX) Genentech unit.
Our table below details the month's major activity:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze